Patents Assigned to CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS
-
Publication number: 20130287772Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.Type: ApplicationFiled: March 1, 2011Publication date: October 31, 2013Applicant: Caris Life Sciences Luxembourg HoldingsInventors: David D. Halbert, Christine Kuslich, George Poste, Micheal Klass, Daniel Spetzler, Andrea Tasinato, Daniel Holterman
-
Publication number: 20130184169Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: ApplicationFiled: April 27, 2012Publication date: July 18, 2013Applicant: Caris Life Sciences Luxembourg Holdings a Luxembourg corporationInventors: Michael KLASS, George POSTE
-
Publication number: 20130005599Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: July 6, 2012Publication date: January 3, 2013Applicants: Caris Life Sciences Luxembourg HoldingsInventors: Michael KLASS, Christine KUSLICH, George POSTE
-
Patent number: 8278059Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: GrantFiled: January 19, 2011Date of Patent: October 2, 2012Assignee: Caris Life Sciences Luxembourg Holdings, S.A.R.L.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Patent number: 8211653Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: GrantFiled: January 19, 2011Date of Patent: July 3, 2012Assignee: Caris Life Sciences Luxembourg Holdings, S.A.R.L.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Patent number: 8192954Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: GrantFiled: December 8, 2010Date of Patent: June 5, 2012Assignee: Caris Life Sciences Luxembourg Holdings, S.A.R.L.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Publication number: 20110237450Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: January 19, 2011Publication date: September 29, 2011Applicant: Caris Life Sciences Luxembourg HoldingsInventors: Michael R. Klass, Christine KUSLICH, George Poste
-
Publication number: 20110159506Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: ApplicationFiled: December 8, 2010Publication date: June 30, 2011Applicant: CARIS LIFE SCIENCES LUXEMBOURG HOLDINGSInventors: MICHAEL KLASS, CHRISTINE KUSTILICH, GEORGE POSTE